- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman | 1 | RTTNews | ||
| Di | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Nasus Pharma names Brendan O'Grady as new CEO | 1 | Investing.com | ||
| Di | Nasus Pharma, Ltd.: Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth | 210 | GlobeNewswire (Europe) | TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| 09.06. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 09.06. | Nasus Pharma reports positive preclinical data for NS003 | 1 | Investing.com | ||
| 26.05. | Nasus Pharma Ltd - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.03. | Citizens senkt Kursziel für Nasus Pharma auf 18 US-Dollar | 1 | Investing.com Deutsch | ||
| 26.03. | Citizens cuts Nasus Pharma stock price target to $18 on valuation | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.03. | Nasus Pharma legt positive Phase-2-Daten für Adrenalin-Nasenspray vor | 1 | Investing.com Deutsch | ||
| 25.03. | Nasus Pharma reports Phase 2 results for intranasal epinephrine | 1 | Investing.com | ||
| 25.03. | Nasus Pharma Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.03. | Nasus Pharma, Ltd.: Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update | 246 | GlobeNewswire (Europe) | Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study... ► Artikel lesen | |
| 18.03. | What's Going On With Nasus Pharma Stock On Wednesday | 1 | Benzinga.com | ||
| 16.03. | Nasus Pharma Stock Hits 52-Week Low - Here's Why | 4 | Benzinga.com | ||
| 16.03. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 16.03. | Nasus Pharma reports faster epinephrine delivery in Phase 2 study | 1 | Investing.com | ||
| 16.03. | Nasus Pharma, Ltd.: Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold | 275 | GlobeNewswire (Europe) | NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4%... ► Artikel lesen | |
| 09.03. | Nasus Pharma to present phase 2 data for intranasal epinephrine | 1 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM BIOPHARMA | 2,492 | 0,00 % | Quantum BioPharma Announces Closing of Debt Settlement | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 61,02 | -1,52 % | Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect? | ||
| ORAMED PHARMACEUTICALS | 3,530 | +3,07 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| OPKO HEALTH | 1,280 | +11,30 % | OPKO Health gives back 17% after sharp post-earnings surge | ||
| OPUS GENETICS | 3,280 | +1,86 % | Opus Genetics stock coverage initiated at TD Cowen on gene therapy | ||
| PROTHENA | 7,004 | -0,48 % | Prothena Corporation plc: Prothena to Report Second Quarter 2026 Financial Results on August 6 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,695 | -1,46 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute | WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx" or the "Company") today issued the following statement in response to recent public claims made... ► Artikel lesen | |
| NEUROGENE | 28,600 | +0,70 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ORIC PHARMACEUTICALS | 9,908 | +3,42 % | Oric Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| REVIVA PHARMACEUTICALS | 0,351 | -0,20 % | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form... ► Artikel lesen | |
| OMNIAB | 1,990 | +0,51 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| ONKURE THERAPEUTICS | 3,850 | +0,79 % | OnKure Aktie: H.C. Wainwright senkt Kursziel nach Neubewertung auf 21 US-Dollar | ||
| PROCESSA PHARMACEUTICALS | 2,150 | 0,00 % | Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product | ||
| PRF TECHNOLOGIES | 1,010 | +1,00 % | PRF Technologies Ltd.: PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms | TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF", "PRF Technologies" or the "Company") today issued a Letter to Shareholders from Efraim Cohen-Arazi... ► Artikel lesen | |
| ANBIO BIOTECHNOLOGY | 9,400 | +6,21 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
NASUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,210 (-6,56 %) liegt der Kurs bei 2,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.